HOME >> BIOLOGY >> NEWS
Case for IBD combination therapy comes from research at Baylor, MIT and Hebrew University

Snowmass, Co. (September 10, 2004) - Inflammatory Bowel Diseases, comprised of Crohn's Disease and ulcerative colitis, are for the most part incurable and their causes are still unknown. About 1 million Americans suffer from IBD and research around the world on new therapeutic strategies against IBD is being reported at a conference sponsored by the American Physiological Society.

On one thing most researchers agree on about IBD: it's very complex. And though it might seem obvious that treating a complex disease might take more than one agent, use of combination therapy hasn't been discussed much in relation to IBD.

Now separate groups working in Houston/Boston and Jerusalem have considered the implications of combination therapy in IBD. They are presenting their papers at the APS conference.

Intestinal Lactobacillus reuteri-based combination therapy directly modulates mucosal pro-inflammatory cytokine production in IL-10 deficient mice.

Probiotics and commensal bacteria represent likely sources for novel therapeutic strategies in inflammatory bowel diseases, and have become increasingly interesting to researchers. Indeed, some probiotic therapy agents are thought to be nearing the clinical trial stage. It is well-known that the human (and animal) gut is full of mostly beneficial bacteria. In IBD and other diseases researchers have taken an approach that reintroduces these positive bacteria, allow them to repopulate the gut and quite often they produce their own anti-inflammatory chemicals. One of the major such "bugs" is the genus Lactobacillus.

The research reported below was carried by James Versalovic and Jeremy Andrew Pena at the Baylor College of Medicine/Texas Children's Hospital, Houston, Texas, and by Arlin B. Rogers, Zhongming Ge and James G. Fox at the Division of Comparative Medicine at Massachusetts Institute of Technology, Cambridge, Mass.

Probiotics have demonstrated efficacy in treating patients
'"/>


10-Sep-2004


Page: 1 2 3

Related biology news :

1. Winning combination to build bone density in children
2. Complex cells likely arose from combination of bacterial and extreme-microbe genomes
3. Researchers zero in on new drug combination strategy
4. IUB researchers to investigate genetic recombinations causes and consequences
5. Mutated protein combination tied to excessive sugar production
6. Clinical study reports findings of combination therapy with DOXIL
7. Novel COX-2 combination treatment may reduce colon cancer risk
8. Drug combination increases life span of mice with ALS
9. A combination of zinc and vitamin A may restore night vision in pregnant Nepalese women
10. Alcohol and thiamine deficiency together: a dangerous combination?
11. Inter-Element Recombination Between Retrotransposons May Be Strategy For Evolution Of Viruses Like HIV

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/7/2019)... ... ... R3 Stem Cell is now offering its comprehensive Online Stem Cell Training ... during checkout is FIFTYOFF and applies to both the one month access and the ... over 12,000 successful stem cell procedures performed nationwide. A couple years ago, R3 began ...
(Date:11/6/2019)... ... 06, 2019 , ... In October, Massachusetts stem cell biotechnology ... about a poorly disclosed deficiency in stem cell treatments. Throughout stem cell ... treating stem cells. This problem affects all patients receiving stem cell treatments, ...
(Date:11/5/2019)... ... November 05, 2019 , ... Catalent, the leading global provider ... and consumer health products, today announced it will present at the upcoming World ... 12 – 14, 2019. , On Wednesday, Nov. 13 at 3:20 p.m., Philip ...
Breaking Biology News(10 mins):
(Date:12/4/2019)... , ... December 03, 2019 , ... A new survey ... Health, Teleflex, and CONMED as the overall best medical sales companies to work for ... Sales survey polled over 1,200 professionals from the MedReps community to identify which ...
(Date:12/4/2019)... , ... December 04, 2019 , ... ... further enhance dissolution and stabilize amorphous materials. Additionally, their PDF Synchrotron methods provide ... ability to describe these compositions both in regulatory and patent applications.  , The ...
(Date:11/22/2019)... ... November 22, 2019 , ... Modality Solutions, ... cold chain validation guide to meet and exceed increasingly stringent regulatory expectations ... biopharmaceutical industry leaders, the September 19, 2019 webinar was well received and ...
(Date:11/12/2019)... ... November 12, 2019 , ... REPROCELL ... have been selected by Lantern Pharma to provided preclinical screening and drug sensitivity ... of data points using panels of unique and genetically edited cell lines from ...
Breaking Biology Technology:
Cached News: